age of prevnar for adults
In 2011, the US Food and Drug Administration (FDA) approved PCV13 for use in adults ≥50 years of age [6], and, in 2016, they expanded the approved age range to include adults 18 to 49 years of age [7]. It is important to note, however, that approval by the FDA is not the same as recommended use. Children who have received one or more doses of Prevnar may complete the 4-dose immunization series with Prevnar 13. Children 15 months through 5 years of age who have received 4 doses of Prevnar may receive one dose of Prevnar 13 to elicit immune responses to the six additional serotypes. This catch-up dose of Prevnar 13 should be administered with an interval of at least 8 weeks after the fourth dose of Prevnar. In the United States, vaccination with Prevnar is recommended for all children younger than 2 years, and for unvaccinated children between 24 and 59 months old who are at high risk for pneumococcal infections. Children under the age of two years fail to mount an adequate response to the 23-valent adult vaccine, and so the 7-valent Pneumococcal Conjugated Vaccine (PCV) (e.g. Prevnar) is used. ●Age ≥65 years – The incidence of pneumococcal disease and the associated mortality are very low in adults under the age of 50. Both the incidence of pneumococcal disease and the mortality rate increase after age 50 and more sharply after age 65 (table 1) [9]. In 2014, the ACIP added a recommendation of PCV13 for all adults ≥65 years of age (table 3) as well as persons >2 years of age who have conditions that place them at substantially increased risk for pneumococcal infection. PPSV is used in selected adults and children ≥2 years of age but not in infants or toddlers <2 years of age since polysaccharide antigens are poorly immunogenic in this age group. ●Pneumococcal conjugate vaccine (PCV) was initially marketed in the United States in 2000 as a 7-valent vaccine, PCV7 (Prevnar 7). Prevnar 13 (PCV13) is produced by Pfizer. It is a tridecavalent vaccine, meaning that it contains thirteen serotypes of pneumococcus (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) which are conjugated to diphtheria carrier protein. Pneumococcal conjugate vaccine (PCV) is a pneumococcal vaccine and a conjugate vaccine used to protect infants, young children, and adults against disease caused by the bacterium Streptococcus pneumoniae (the pneumococcus). Prevnar 13 was approved by the U.S. Food and Drug Administration on February 24, 2010. After waiting for the outcome of a trial underway in the Netherlands, the Centers for Disease Control and Prevention (CDC) recommended the vaccine for adults over age 65 in August 2014.
Age 65